{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:24Z","timestamp":1760576004658,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.clon.2013.10.007","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T02:00:16Z","timestamp":1384567216000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience"],"prefix":"10.1016","volume":"26","author":[{"given":"I.E.G.","family":"van Hellemond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.C.","family":"van Warmerdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.T.","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2013.10.007_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2013.10.007_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.seminoncol.2011.05.009","article-title":"Treatment of metastatic colorectal cancer","volume":"38","author":"Davies","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ctrv.2011.08.002","article-title":"Biologic therapies in the metastatic colorectal cancer treatment continuum: applying current evidence to clinical practice","volume":"38","author":"Peeters","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2013.10.007_bib4","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib6","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","article-title":"First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer","volume":"138","author":"K\u00f6hne","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib8","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1081\/CNV-58878","article-title":"Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer","volume":"23","author":"Goldstein","year":"2005","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clon.2013.10.007_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/172460080301800408","article-title":"Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer","volume":"18","author":"Massacesi","year":"2003","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.clon.2013.10.007_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.clon.2003.11.005","article-title":"Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?","volume":"16","author":"Trillet-Lenoir","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1245\/s10434-009-0887-5","article-title":"Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases","volume":"17","author":"de Haas","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/07357907.2011.629380","article-title":"CEA and CA19.9 as early predictors of progression in advanced\/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab","volume":"30","author":"Petrioli","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clon.2013.10.007_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/172460080802300408","article-title":"Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer","volume":"23","author":"Tsai","year":"2008","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.clon.2013.10.007_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"year":"2009","series-title":"Common Terminology Criteria for Adverse Events (CTCAE v3.0)","author":"Cancer Therapy Evaluation Program","key":"10.1016\/j.clon.2013.10.007_bib16"},{"key":"10.1016\/j.clon.2013.10.007_bib17","first-page":"333","article-title":"The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) by KRAS status","volume":"10","author":"Mitchell","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clon.2013.10.007_bib18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib19","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib21","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib22","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2008.17.1249","article-title":"Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma","volume":"26","author":"Haller","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib24","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","article-title":"Phase II trial of irinotecan in patients with metastatic colorectal carcinoma","volume":"15","author":"Pitot","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib25","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.10.007_bib26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdn730","article-title":"Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study","volume":"20","author":"Bidard","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/CAD.0b013e32833c57cf","article-title":"Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer","volume":"21","author":"Oostendorp","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clon.2013.10.007_bib29","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2013.10.007_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2011.09.004","article-title":"Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review","volume":"38","author":"Baas","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2013.10.007_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513004238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513004238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:39:09Z","timestamp":1760542749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513004238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0936655513004238"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.10.007","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}